THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [11.10] ID: TIP-MED-000214

Carbamazepine (and Oxcarbazepine comparison)

Active Ingredient / Scientific Identity: Carbamazepine • Class: Iminostilbene Voltage-Gated Sodium Channel Blocker (Antiepileptic, Trigeminal Neuralgia Specific Analgesic & Mood Stabiliser; Potent Pan-CYP/P-gp Enzyme Inducer)

⚖️ Compare Profile
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Carbamazepine (and Oxcarbazepine comparison) ([11.10] | ID: TIP-MED-000214) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/11-10-carbamazepine-and-oxcarbazepine-comparison/
Generic / Entity NameCarbamazepine (and Oxcarbazepine comparison) ([11.10])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassIminostilbene Voltage-Gated Sodium Channel Blocker (Antiepileptic, Trigeminal Neuralgia Sp
Available Dosage FormsImmediate-Release Tablets: 100 mg, 200 mg, 400 mg; Controlled/Sustained-Release (CR/SR/Retard) Scored Tablets:
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: Excreted <3% unchanged; monitor sodium closely in CKD. Hepatic: Metabolised >95% hepatically; avoid in active liver di
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Carbamazepine (and Oxcarbazepine comparison) (TIP-MED-000214, Reference Code [11.10]) is classified under Neurology & Antiepileptic Medicines (Ch 11) as a Iminostilbene Voltage-Gated Sodium Channel Blocker (Antiepileptic, Trigeminal Neuralgia Specific Analgesic & Mood Stabiliser; Potent Pan-CYP/P-gp Enzyme Inducer). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 11 [11.10], p. 144): Tegretol (Novartis—IR & CR), Mazetol / Mazetol-SR (Abbott), Zen / Zen-Retard (Intas), Zeptol-CR (Sun Pharma). (Related keto-analogue with fewer CYP interactions but higher hyponatraemia rate: Oxcarbazepine [Trileptal, Oxetol, Oleptal 150/300/600 mg]) — Strengths & Dosage Forms: Immediate-Release Tablets: 100 mg, 200 mg, 400 mg; Controlled/Sustained-Release (CR/SR/Retard) Scored Tablets: 200 mg, 300 mg, 400 mg; Oral Syrup: 100 mg/5 mL
Representative Indian Market Examples (Edition 2.7 Ch 11 [11.10], p. 144): Tegretol (Novartis—IR & CR), Mazetol / Mazetol-SR (Abbott), Zen / Zen-Retard (Intas), Zeptol-CR (Sun Pharma). (Related keto-analogue with fewer CYP interactions but higher hyponatraemia rate: Oxcarbazepine [Trileptal, Oxetol, Oleptal 150/300/600 mg]) — Strengths & Dosage Forms: Immediate-Release Tablets: 100 mg, 200 mg, 400 mg; Controlled/Sustained-Release (CR/SR/Retard) Scored Tablets: 200 mg, 300 mg, 400 mg; Oral Syrup: 100 mg/5 mL
Dosage Forms & Available Strengths:
Immediate-Release Tablets: 100 mg, 200 mg, 400 mg; Controlled/Sustained-Release (CR/SR/Retard) Scored Tablets: 200 mg, 300 mg, 400 mg; Oral Syrup: 100 mg/5 mL
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Iminostilbene Voltage-Gated Sodium Channel Blocker (Antiepileptic, Trigeminal Neuralgia Specific Analgesic & Mood Stabiliser; Potent Pan-CYP/P-gp Enzyme Inducer) acting on target receptor/enzyme pathways in Neurology & Antiepileptic Medicines (Ch 11): clinical efficacy is mediated via Iminostilbene Voltage-Gated Sodium Channel Blocker (Antiepileptic, Trigeminal Neuralgia Specific Analgesic & Mood Stabiliser; Potent Pan-CYP/P-gp Enzyme Inducer) for First-line Drug of Choice for Trigeminal Neuralgia (Tic Douloureux) and Glossopharyngeal Neuralgia; focal-onset (partial) seizures with or without secondary generalization; bipolar disorder maintenance..

4. Therapeutic Indications & Evidence-Supported Uses

  • First-line Drug of Choice for Trigeminal Neuralgia (Tic Douloureux) and Glossopharyngeal Neuralgia
  • focal-onset (partial) seizures with or without secondary generalization
  • bipolar disorder maintenance

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: General Adult Reference: Auto-Induction Pharmacokinetics! Carbamazepine induces its own hepatic CYP3A4 metabolism over the first 2 to 4 weeks (reducing its own half-life from 30 hours down to 12 hours!), so it MUST be started low and titrated gradually: • Trigeminal Neuralgia: Start at 100 mg twice daily (in elderly: 50–100 mg BD); increase by 100 mg every 3–7 days to pain relief (usually 200 mg–400 mg BD; max 1200 mg/day). • Epilepsy: Start 100–200 mg BD, titrate to 400–600 mg BD (Therapeutic trough level: 4 to 12 mcg/mL). Follow neurologist prescription.

Administration & Meal Timing: Take WITH meals! (Food and bile salts significantly enhance the dissolution and bioavailability of lipophilic carbamazepine and reduce GI nausea). Swallow CR/Retard tablets whole (or halved strictly along the manufacturer score line if scored pellet tablet like Tegretol-CR; never crush or chew!). | Twice daily after breakfast and dinner (for CR/Retard formulations).

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: Excreted <3% unchanged; monitor sodium closely in CKD. Hepatic: Metabolised >95% hepatically; avoid in active liver disease and monitor LFTs.
Elimination & Renal Adjustment:
Renal: Excreted <3% unchanged; monitor sodium closely in CKD. Hepatic: Metabolised >95% hepatically; avoid in active liver disease and monitor LFTs.
Hepatic Impairment Considerations:
Renal: Excreted <3% unchanged; monitor sodium closely in CKD. Hepatic: Metabolised >95% hepatically; avoid in active liver disease and monitor LFTs.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • 1. MANDATORY HLA-B*15:02 PHARMACOGENOMIC WARNING IN INDIANS / SOUTH ASIANS: The HLA-B*15:02 allele (and HLA-A*31:01) is present in a significant subset of the Indian population and confers a >10- to 50-fold increased risk of fatal Carbamazepine-induced Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) during the first 8 weeks of therapy! 2. Contraindicated in AV Conduction Block, history of bone marrow depression, hepatic porphyria, and within 14 days of MAOIs. 3. Worsens Absence and Myoclonic Seizures!

Key Clinical Precautions: Renal: Excreted <3% unchanged; monitor sodium closely in CKD. Hepatic: Metabolised >95% hepatically; avoid in active liver disease and monitor LFTs.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Peak-concentration neurotoxicity (dizziness, vertigo, ataxia/unsteady gait, diplopia [double vision], blurred vision, nystagmus, drowsiness—markedly reduced by using Controlled-Release [CR/Retard] tablets instead of plain IR!), nausea, mild benign leukopenia (~10% of patients).
  • Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and DRESS Syndrome (90% occur within the first 14 to 60 days of starting therapy!), Severe SIADH Hyponatraemia (Na+ <125 mEq/L—especially in elderly patients and even more frequent with Oxcarbazepine!), Aplastic Anaemia and Agranulocytosis, AV nodal heart block / bradyarrhythmias in the elderly, hepatotoxicity, osteomalacia (Vitamin D catabolism).
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • POTENT PAN-INDUCER OF CYP3A4, CYP2C9, CYP1A2, UGT, AND P-GLYCOPROTEIN! Carbamazepine accelerates the hepatic breakdown and CAUSES COMPLETE THERAPEUTIC FAILURE of: • Direct Oral Anticoagulants (Apixaban, Rivaroxaban, Dabigatran—CONTRAINDICATED, causes stroke/clots!) and Warfarin (drops INR by 50%!)
  • • Calcium Channel Blockers (Amlodipine, Nimodipine, Felodipine), Statins (Atorvastatin, Simvastatin), Corticosteroids (Prednisolone, Dexamethasone), Levothyroxine, Cyclosporine/Tacrolimus, Oral Contraceptives, Itraconazole, Doxycycline, and Haloperidol/Risperidone/Quetiapine! 2
  • CYP3A4 Inhibitors that Cause Acute Carbamazepine Toxicity (ataxia, double vision, coma): Clarithromycin, Erythromycin, Fluconazole, Itraconazole, Verapamil, Diltiazem, Cimetidine, and Sodium Valproate (Valproate inhibits epoxide hydrolase, causing toxic accumulation of active Carbamazepine-10,11-epoxide even when parent carbamazepine levels look normal!)

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: 1. Always dispense Controlled-Release (Tegretol-CR / Mazetol-SR / Zeptol-CR) when specified—switching a patient from CR to plain IR causes sudden spikes of double vision and staggering 2 hours after each dose! 2. Urgent SJS Skin & Blood Warning: Instruct the patient to stop the tablet and report to the emergency room immediately if any skin rash, fever, sore throat, mouth/lip blisters, red eyes, or easy bruising develops (especially during the first 2 months). 3. Check if the patient is taking any blood thinner (Apixaban/Rivaroxaban/Warfarin) or Amlodipine/Atorvastatin, as Carbamazepine destroys their levels in the body!
  • Meal & Clock Timing Instruction: Take WITH meals! (Food and bile salts significantly enhance the dissolution and bioavailability of lipophilic carbamazepine and reduce GI nausea). Swallow CR/Retard tablets whole (or halved strictly along the manufacturer score line if scored pellet tablet like Tegretol-CR; never crush or chew!). (Twice daily after breakfast and dinner (for CR/Retard formulations).)
  • Missed Dose Protocol: Take with food as soon as remembered unless within 4–6 hours of next scheduled dose; never double.
  • Geriatric Dispensing Pearl: In elderly CGHS patients prescribed Carbamazepine (or Oxcarbazepine) for Trigeminal Neuralgia, monitor closely for three major geriatric hazards: (1) Severe Hyponatraemia (SIADH) (especially if also taking a thiazide diuretic or SSRI!), (2) Bradycardia/AV heart block, and (3) Loss of efficacy of their concurrent anticoagulant and antihypertensive drugs.

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Immediate-Release Tablets: 100 mg, 200 mg, 400 mg; Controlled/Sustained-Release (CR/SR/Retard) Scored Tablets: 200 mg, 300 mg, 400 mg; Oral Syrup: 100 mg/5 mL

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 11 [11.10] (p. 144)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/11-10-carbamazepine-and-oxcarbazepine-comparison/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.